C92.2 Atypical chronic myeloid leukemia, BCR/ABL-negative

Name of the Condition

• Atypical chronic myeloid leukemia, BCR/ABL-negative

Summary

Atypical chronic myeloid leukemia (aCML) is a rare myeloproliferative neoplasm characterized by the overproduction of abnormal myeloid cells in the bone marrow. Unlike classic chronic myeloid leukemia (CML), aCML lacks the BCR/ABL fusion gene and exhibits distinct clinical and genetic features. The condition disrupts normal blood cell production, leading to anemia, thrombocytopenia, or leukocytosis, and may progress to acute leukemia.

Causes

aCML arises from genetic mutations in hematopoietic stem cells, though the specific mutations differ from those in BCR/ABL-positive CML. Common alterations involve genes regulating cell growth and differentiation, such as SETBP1, ETNK1, or ASXL1. These mutations drive uncontrolled proliferation of myeloid cells and impair normal maturation.

Risk Factors

• Age: Primarily affects older adults, with incidence increasing after age 60.
• Prior myelodysplastic syndromes or other myeloid neoplasms.
• Exposure to certain chemotherapy agents or radiation (less common).
• No strong association with inherited genetic predisposition.

Symptoms

• Fatigue or weakness due to anemia.
• Unexplained weight loss or fever.
• Easy bruising or bleeding from low platelet counts.
• Frequent infections due to neutropenia.
• Enlarged spleen (splenomegaly) or abdominal discomfort.
• Bone pain or joint aches.

Diagnosis

Diagnosis requires a combination of blood tests to evaluate cell counts and morphology, followed by a bone marrow biopsy to assess cellularity and dysplasia. Cytogenetic or molecular testing confirms the absence of the BCR/ABL fusion gene and identifies other mutations. Differential diagnosis excludes other myeloproliferative or myelodysplastic disorders.

Treatment Options

Treatment is tailored to the patient’s age, overall health, and disease severity. Options may include hypomethylating agents (e.g., azacitidine), targeted therapies for specific mutations, or allogeneic stem cell transplantation for eligible patients. Supportive care addresses symptoms like anemia or infections.

Prognosis and Follow-Up

Prognosis is generally poorer than for BCR/ABL-positive CML due to limited treatment responses. Regular monitoring of blood counts, bone marrow status, and genetic markers is essential. Follow-up intervals depend on treatment response and risk of progression to acute leukemia.

Complications

• Progression to acute myeloid leukemia (AML).
• Severe anemia, thrombocytopenia, or neutropenia.
• Increased risk of infections or bleeding.
• Organ damage from leukemic cell infiltration (e.g., spleen, liver).

Lifestyle & Prevention

• Avoid exposure to known carcinogens (e.g., benzene, certain chemotherapies).
• Maintain a balanced diet and regular exercise to support overall health.
• Promptly address infections or unexplained symptoms to prevent complications.

When to Seek Professional Help

Seek medical attention for persistent fatigue, unexplained weight loss, easy bruising, or recurrent infections. Immediate care is needed for severe bleeding, high fever, or sudden worsening of symptoms.

Tips for Medical Coders

Document the absence of the BCR/ABL fusion gene and any confirmed genetic mutations (e.g., SETBP1, ETNK1) to support the diagnosis. Ensure laboratory results and bone marrow biopsy findings are clearly recorded, as these are critical for coding accuracy.